Volume | 895,697 |
|
|||||
News | - | ||||||
Day High | 13.97 | Low High |
|||||
Day Low | 13.45 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sage Therapeutics Inc | SAGE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
13.46 | 13.45 | 13.97 | 13.94 | 13.105 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
13,596 | 895,697 | $ 13.63 | $ 12,209,557 | - | 10.92 - 59.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:47:26 | formt | 300 | $ 13.71 | USD |
Sage Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
839.09M | 60.11M | - | 86.46M | -541.49M | -9.01 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sage Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SAGE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 13.87 | 14.71 | 12.84 | 13.59 | 1,111,001 | -0.16 | -1.15% |
1 Month | 16.47 | 17.045 | 10.92 | 14.06 | 1,301,772 | -2.76 | -16.76% |
3 Months | 23.85 | 27.39 | 10.92 | 18.43 | 1,090,591 | -10.14 | -42.52% |
6 Months | 19.66 | 28.26 | 10.92 | 20.32 | 977,615 | -5.95 | -30.26% |
1 Year | 46.59 | 59.99 | 10.92 | 25.09 | 1,105,920 | -32.88 | -70.57% |
3 Years | 79.29 | 80.23 | 10.92 | 34.31 | 775,159 | -65.58 | -82.71% |
5 Years | 165.88 | 193.56 | 10.92 | 49.17 | 756,908 | -152.17 | -91.73% |
Sage Therapeutics Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development. |